| [1] |
SUNG H, FERLAY J, SIEGEL RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660. |
| [2] |
MELIALA I, HOSEA R, KASIM V, et al. The biological implications of Yin Yang 1 in the hallmarks of cancer[J]. Theranostics, 2020, 10(9): 4183-4200. DOI: 10.7150/thno.43481. |
| [3] |
SARVAGALLA S, KOLAPALLI SP, VALLABHAPURAPU S. The two sides of YY1 in cancer: A friend and a foe[J]. Front Oncol, 2019, 9: 1230. DOI: 10.3389/fonc.2019.01230. |
| [4] |
MARTINEZ-RUIZ GU, MORALES-SANCHEZ A, PACHECO-HERNANDEZ AF. Roles played by YY1 in embryonic, adult and cancer stem cells[J]. Stem Cell Rev Rep, 2021, 17(5): 1590-1606. DOI: 10.1007/s12015-021-10151-9. |
| [5] |
LEE JS, SEE RH, GALVIN KM, et al. Functional interactions between YY1 and adenovirus E1A[J]. Nucleic Acids Res, 1995, 23(6): 925-931. DOI: 10.1093/nar/23.6.925. |
| [6] |
LIU D, ZHANG J, WU Y, et al. YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway[J]. Int J Cancer, 2018, 142(7): 1392-1404. DOI: 10.1002/ijc.31173. |
| [7] |
SHEN B, LI Y, YE Q, et al. YY1-mediated long non-coding RNA Kcnq1ot1 promotes the tumor progression by regulating PTEN via DNMT1 in triple negative breast cancer[J]. Cancer Gene Ther, 2021, 28(10-11): 1099-1112. DOI: 10.1038/s41417-020-00254-9. |
| [8] |
WANG L, GAO Y, ZHAO X, et al. HOXD3 was negatively regulated by YY1 recruiting HDAC1 to suppress progression of hepatocellular carcinoma cells via ITGA2 pathway[J]. Cell Prolif, 2020, 53(8): e12835. DOI: 10.1111/cpr.12835. |
| [9] |
ZHANG L, CAI X, CHEN K, et al. Hepatitis B virus protein up-regulated HLJ1 expression via the transcription factor YY1 in human hepatocarcinoma cells[J]. Virus Res, 2011, 157(1): 76-81. DOI: 10.1016/j.virusres.2011.02.009. |
| [10] |
YANG W, LI Z, QIN R, et al. YY1 Promotes endothelial cell-dependent tumor angiogenesis in hepatocellular carcinoma by transcriptionally activating VEGFA[J]. Front Oncol, 2019, 9: 1187. DOI: 10.3389/fonc.2019.01187. |
| [11] |
XUAN W, ZHOU C, YOU G. LncRNA LINC00668 promotes cell proliferation, migration, invasion ability and EMT process in hepatocellular carcinoma by targeting miR-532-5p/YY1 axis[J]. Biosci Rep, 2020, 40(5): BSR20192697. DOI: 10.1042/BSR20192697. |
| [12] |
XU XP, PENG XQ, YIN XM, et al. miR-34a-5p suppresses the invasion and metastasis of liver cancer by targeting the transcription factor YY1 to mediate MYCT1 upregulation[J]. Acta Histochem, 2020, 122(6): 151576. DOI: 10.1016/j.acthis.2020.151576. |
| [13] |
ZHANG S, JIANG T, FENG L, et al. Yin Yang-1 suppresses differentiation of hepatocellular carcinoma cells through the downregulation of CCAAT/enhancer-binding protein alpha[J]. J Mol Med (Berl), 2012, 90(9): 1069-1077. DOI: 10.1007/s00109-012-0879-y. |
| [14] |
LUO YD, FANG L, YU HQ, et al. p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma[J]. J Hepatol, 2021, 74(1): 96-108. DOI: 10.1016/j.jhep.2020.07.036. |
| [15] |
GRÖNROOS E, TERENTIEV AA, PUNGA T, et al. YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress[J]. Proc Natl Acad Sci U S A, 2004, 101(33): 12165-12170. DOI: 10.1073/pnas.0402283101. |
| [16] |
NOTARBARTOLO M, GIANNITRAPANI L, VIVONA N, et al. Frequent alteration of the Yin Yang 1/Raf-1 kinase inhibitory protein ratio in hepatocellular carcinoma[J]. OMICS, 2011, 15(5): 267-272. DOI: 10.1089/omi.2010.0096. |
| [17] |
MEI C, JIANG X, GU Y, et al. YY1-mediated reticulocalbin-2 upregulation promotes the hepatocellular carcinoma progression via activating MYC signaling[J]. Am J Cancer Res, 2021, 11(5): 2238-2251.
|
| [18] |
DING D, HUANG H, JIANG W, et al. Reticulocalbin-2 enhances hepatocellular carcinoma proliferation via modulating the EGFR-ERK pathway[J]. Oncogene, 2017, 36(48): 6691-6700. DOI: 10.1038/onc.2017.230. |
| [19] |
WANG Y, DOU L, QIN Y, et al. OIP5-AS1 contributes to tumorigenesis in hepatocellular carcinoma by miR-300/YY1-activated WNT pathway[J]. Cancer Cell Int, 2020, 20: 440. DOI: 10.1186/s12935-020-01467-6. |
| [20] |
PETKOVA V, ROMANOWSKI MJ, SULIJOADIKUSUMO I, et al. Interaction between YY1 and the retinoblastoma protein. Regulation of cell cycle progression in differentiated cells[J]. J Biol Chem, 2001, 276(11): 7932-7936. DOI: 10.1074/jbc.M007411200. |
| [21] |
WANG X, FENG Y, XU L, et al. YY1 restrained cell senescence through repressing the transcription of p16[J]. Biochim Biophys Acta, 2008, 1783(10): 1876-1883. DOI: 10.1016/j.bbamcr.2008.05.015. |
| [22] |
TSANG DP, WU WK, KANG W, et al. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma[J]. J Pathol, 2016, 238(5): 651-664. DOI: 10.1002/path.4688. |
| [23] |
ODABAEI G, CHATTERJEE D, JAZIREHI AR, et al. Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis[J]. Adv Cancer Res, 2004, 91: 169-200. DOI: 10.1016/S0065-230X(04)91005-6. |
| [24] |
E CY. The research of the DR4 and DR5 expressions in hepatocellular carcinoma apoptosis induced by TRAIL[D]. Changchun: Jilin University, 2008.
鄂长勇. 死亡受体DR4和DR5的表达在TRAIL诱导肝癌细胞凋亡中的研究[D]. 长春: 吉林大学, 2008.
|
| [25] |
BARITAKI S, HUERTA-YEPEZ S, SAKAI T, et al. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1[J]. Mol Cancer Ther, 2007, 6(4): 1387-1399. DOI: 10.1158/1535-7163.MCT-06-0521. |
| [26] |
ALLOUCHE A, NOLENS G, TANCREDI A, et al. The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors[J]. Breast Cancer Res, 2008, 10(1): R9. DOI: 10.1186/bcr1851. |
| [27] |
HAN J, MENG J, CHEN S, et al. YY1 complex promotes quaking expression via super-enhancer binding during EMT of hepatocellular carcinoma[J]. Cancer Res, 2019, 79(7): 1451-1464. DOI: 10.1158/0008-5472.CAN-18-2238. |
| [28] |
CHO AA, BONAVIDA B. Targeting the overexpressed YY1 in cancer inhibits EMT and metastasis[J]. Crit Rev Oncog, 2017, 22(1-2): 49-61. DOI: 10.1615/CritRevOncog.2017020473. |
| [29] |
KALLURI R, WEINBERG RA. The basics of epithelial-mesenchymal transition[J]. J Clin Invest, 2009, 119(6): 1420-1428. DOI: 10.1172/JCI39104. |
| [30] |
PALMER MB, MAJUMDER P, COOPER JC, et al. Yin yang 1 regulates the expression of snail through a distal enhancer[J]. Mol Cancer Res, 2009, 7(2): 221-229. DOI: 10.1158/1541-7786.MCR-08-0229. |
| [31] |
CANO A, PÉREZ-MORENO MA, RODRIGO I, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression[J]. Nat Cell Biol, 2000, 2(2): 76-83. DOI: 10.1038/35000025. |
| [32] |
MARTÍNEZ-ESTRADA OM, CULLERÉS A, SORIANO FX, et al. The transcription factors Slug and Snail act as repressors of Claudin-1 expression in epithelial cells[J]. Biochem J, 2006, 394(Pt 2): 449-457. DOI: 10.1042/BJ20050591. |
| [33] |
MYONG NH. Loss of E-cadherin and acquisition of vimentin in epithelial-mesenchymal transition are noble indicators of uterine cervix cancer progression[J]. Korean J Pathol, 2012, 46(4): 341-348. DOI: 10.4132/KoreanJPathol.2012.46.4.341. |
| [34] |
HAO L, HA JR, KUZEL P, et al. Cadherin switch from E- to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through Twist and Snail[J]. Br J Dermatol, 2012, 166(6): 1184-1197. DOI: 10.1111/j.1365-2133.2012.10824.x. |
| [35] |
STANISAVLJEVIC J, PORTA-de-la-RIVA M, BATLLE R, et al. The p65 subunit of NF-κB and PARP1 assist Snail1 in activating fibronectin transcription[J]. J Cell Sci, 2011, 124(Pt 24): 4161-4171. DOI: 10.1242/jcs.078824. |
| [36] |
|
| [37] |
WU S, KASIM V, KANO MR, et al. Transcription factor YY1 contributes to tumor growth by stabilizing hypoxia factor HIF-1α in a p53-independent manner[J]. Cancer Res, 2013, 73(6): 1787-1799. DOI: 10.1158/0008-5472.CAN-12-0366. |
| [38] |
de NIGRIS F, CRUDELE V, GIOVANE A, et al. CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy[J]. Proc Natl Acad Sci U S A, 2010, 107(32): 14484-14489. DOI: 10.1073/pnas.1008256107. |
| [39] |
SITWALA KV, ADAMS K, MARKOVITZ DM. YY1 and NF-Y binding sites regulate the transcriptional activity of the dek and dek-can promoter[J]. Oncogene, 2002, 21(57): 8862-8870. DOI: 10.1038/sj.onc.1206041. |
| [40] |
ZHANG Y, LIU J, WANG S, et al. The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners[J]. Oncotarget, 2016, 7(17): 23740-23756. DOI: 10.18632/oncotarget.8060. |
| [41] |
CHEN MS, HU ZL. Research progress of hepatic arterial infusion chemotherapy in the conversion therapy of hepatocellular carcinoma[J]. Chin J Dig Surg, 2021, 20(2): 171-177. DOI: 10.3760/cma.j.cn115610-20201230-00813. |
| [42] |
DONG S, MA X, WANG Z, et al. YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitor[J]. Oncotarget, 2017, 8(25): 40583-40593. DOI: 10.18632/oncotarget.17196. |
| [43] |
WEI JY, SUN W, LIU XM, et al. Advances in targated therapy and immunotherapy for hepatocellular carcinoma[J]. J Clin Hepatol, 2020, 36(10): 2320-2324. DOI: 10.3969/j.issn.1001-5256.2020.10.035. |
| [44] |
ZOU W, WOLCHOK JD, CHEN L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations[J]. Sci Transl Med, 2016, 8(328): 328rv4. DOI: 10.1126/scitranslmed.aad7118. |
| [45] |
HAYS E, BONAVIDA B. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression[J]. Drug Resist Updat, 2019, 43: 10-28. DOI: 10.1016/j.drup.2019.04.001. |
| [46] |
CORTEZ MA, IVAN C, VALDECANAS D, et al. PDL1 regulation by p53 via miR-34[J]. J Natl Cancer Inst, 2016, 108(1): djv303. DOI: 10.1093/jnci/djv303. |
| [47] |
KIM JS, SON SH, KIM MY, et al. Diagnostic and prognostic relevance of CP2c and YY1 expression in hepatocellular carcinoma[J]. Oncotarget, 2017, 8(15): 24389-24400. DOI: 10.18632/oncotarget.15462. |
| [48] |
HUANG YP, LUO WX, XU LB. Expression and function of transcription factor YY1 in hepatocellular carcinoma[J]. Lingnan Mod Clin Surg, 2021, 21(1): 44-52, 58. DOI: 10.3969/j.issn.1009-976X.2021.01.008. |
DownLoad:
